Geburtshilfe Frauenheilkd 2022; 82(10): e119-e120
DOI: 10.1055/s-0042-1756936
Abstracts | DGGG

Adjuvant endocrine therapy combined with abemaciclib in monarchE patients with high-risk early breast cancer: disease characteristics and endocrine therapy choice by menopausal status

HJ Lück
1   Gynäkologisch-Onkologische Praxis Hannover, Hannover, Deutschland
,
S Paluch-Shimon
2   Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel
,
J Beith
3   Chris O'Brien Lifehouse Centre, Sydney, Australien
,
E Tokunaga
4   National Hospital Organization Kyushu Cancer Center, Department of Breast Oncology, Fukuoka, Japan
,
J Reyes Contreras
5   Oncológico Potosino, San Luis Potosí, Mexiko
,
R Oliveira de Sant’Ana
6   Instituto do Câncer do Ceará, Division of Clinical Oncology, Fortaleza, Brasilien
,
T Forrester
7   Eli Lilly and Company, Indianapolis, Indiana, Vereinigte Staaten
,
R McNaughton
7   Eli Lilly and Company, Indianapolis, Indiana, Vereinigte Staaten
,
J Wei
8   Eli Lilly and Company, Indianapolis, Indiana, Deutschland
,
N Harbeck
9   Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center, LMU University Hospital, München, Deutschland
› Author Affiliations
› Further Information
Also available at
 

Objectives MonarchE demonstrated that adjuvant abemaciclib, oral CDK4 & 6 inhibitor+endocrine therapy (ET) significantly improved invasive disease-free survival in HR+, HER2- high-risk early breast cancer (EBC) versus ET-alone. As prescribing practices for ET vary in younger patients, we present disease characteristics and ET choice in premenopausal patients (preM) enrolled in monarchE.

Materials/methods Patients with invasive, resected, HR+, HER2- node-positive, high-risk, EBC were randomly assigned 1:1 to adjuvant ET +/- abemaciclib in monarchE. Disease characteristics, prior chemotherapy, and ET patterns were examined by menopausal status at initial diagnosis: preM and postmenopausal patients (postM). ET choices for preM are further described by age.

Results Of the 5637 patients, 43.5%/56.5% were preM/postM, with an even distribution between both arms. Median age for preM/postM was 44/59 years (y); 31.5% preM were ≤40y.

PreM had larger tumor size (abemaciclib+ET/ET-alone [N=1227/1224]; ≥5cm=21/21%) vs postM (abemaciclib+ET/ET-alone [N=1576/1605]=15/14%). PreM had higher rates of neoadjuvant chemotherapy administration (abemaciclib+ET/ET-alone=42/42%) vs postM (32/32%). Aromatase inhibitor (AI) use was higher in postM (abemaciclib+ET/ET-alone=90/89%) vs preM (43/40%); tamoxifen use was higher in preM (57/59%) vs postM (10/11%).

Among preM, AI use was highest in preM ≤40y in both arms (abemaciclib+ET=49.9%/ET=49.4%) and tamoxifen use was highest in preM >40y to ≤50y in both abemaciclib+ET (60.1%) and ET arms (65.0%).

Summary PreM had larger tumors at baseline and were more likely to have received neoadjuvant chemotherapy, suggesting they may have a higher risk of recurrence than PostM.

Previously presented at ESMO Congress 2021, “FPN (Final Publication Number):153P”, “Shani Paluch-Shimon et al.”-Reused with permission.



Publication History

Article published online:
11 October 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany